The Hallmarks of Glioblastoma: Heterogeneity, Intercellular Crosstalk and Molecular Signature of Invasiveness and Progression.

glioblastoma immune modulation invasiveness metabolism stress response

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
30 Mar 2022
Historique:
received: 18 03 2022
revised: 26 03 2022
accepted: 29 03 2022
entrez: 23 4 2022
pubmed: 24 4 2022
medline: 24 4 2022
Statut: epublish

Résumé

In 2021 the World Health Organization published the fifth and latest version of the Central Nervous System tumors classification, which incorporates and summarizes a long list of updates from the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy work. Among the adult-type diffuse gliomas, glioblastoma represents most primary brain tumors in the neuro-oncology practice of adults. Despite massive efforts in the field of neuro-oncology diagnostics to ensure a proper taxonomy, the identification of glioblastoma-tumor subtypes is not accompanied by personalized therapies, and no improvements in terms of overall survival have been achieved so far, confirming the existence of open and unresolved issues. The aim of this review is to illustrate and elucidate the state of art regarding the foremost biological and molecular mechanisms that guide the beginning and the progression of this cancer, showing the salient features of tumor hallmarks in glioblastoma. Pathophysiology processes are discussed on molecular and cellular levels, highlighting the critical overlaps that are involved into the creation of a complex tumor microenvironment. The description of glioblastoma hallmarks shows how tumoral processes can be linked together, finding their involvement within distinct areas that are engaged for cancer-malignancy establishment and maintenance. The evidence presented provides the promising view that glioblastoma represents interconnected hallmarks that may led to a better understanding of tumor pathophysiology, therefore driving the development of new therapeutic strategies and approaches.

Identifiants

pubmed: 35453557
pii: biomedicines10040806
doi: 10.3390/biomedicines10040806
pmc: PMC9031586
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Fondazione Umberto Veronesi
ID : Filippo Torrisi
Organisme : PhD program in Biotechnology (Biometec, University of Catania, Italy)
ID : Cristiana Alberghina
Organisme : PhD program in Biotechnology (Biometec, University of Catania, Italy)
ID : Anna M. Pavone
Organisme : PhD program in Neuroscience (Biometec, University of Catania, Italy)
ID : Simona D'Aprile
Organisme : PON AIM R&I 2014-2020
ID : E66C18001240007
Organisme : Piano di Incentivi per la ricerca di Ateneo 2020-2022, Linea di Intervento 2
ID : MD-RESETT-GLIO
Organisme : Ministero Italiano dell'Istruzione, dell'Università e della Ricerca, PRIN 2017
ID : 2017XKWWK9_004

Références

N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Curr Cancer Drug Targets. 2010 Dec;10(8):840-8
pubmed: 20718706
ESMO Open. 2017 Feb 22;1(6):e000144
pubmed: 28912963
Neuro Oncol. 2015 Sep;17(9):1220-30
pubmed: 25712957
Clin Cancer Res. 2019 Jan 15;25(2):844-855
pubmed: 30322879
Neurosurg Focus. 2014 Dec;37(6):E11
pubmed: 25434380
Cancer Invest. 2012 Jan;30(1):48-56
pubmed: 22236189
Cells. 2021 Jan 20;10(2):
pubmed: 33498369
Int J Mol Sci. 2020 Aug 06;21(16):
pubmed: 32781585
Nat Rev Clin Oncol. 2018 Jul;15(7):422-442
pubmed: 29643471
Cancer Lett. 2015 Jun 28;362(1):1-7
pubmed: 25796440
Oncotarget. 2017 May 25;8(34):57813-57825
pubmed: 28915713
Neuro Oncol. 2020 Sep 29;22(9):1249-1261
pubmed: 32391559
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
CNS Oncol. 2020 Sep 1;9(3):CNS62
pubmed: 32716208
Front Immunol. 2018 Dec 21;9:2924
pubmed: 30619286
Acta Neuropathol Commun. 2019 Nov 29;7(1):203
pubmed: 31815646
Front Oncol. 2019 Nov 01;9:1143
pubmed: 31737570
Front Oncol. 2014 Mar 24;4:47
pubmed: 24716189
Front Mol Biosci. 2021 Jan 27;7:620677
pubmed: 33585565
Clin Cancer Res. 2016 Oct 1;22(19):4797-4806
pubmed: 27143690
Front Oncol. 2021 Aug 26;11:692650
pubmed: 34513675
Front Oncol. 2017 Jul 10;7:143
pubmed: 28740831
Oncol Lett. 2016 Oct;12(4):2283-2288
pubmed: 27698790
Clin Exp Metastasis. 2019 Jun;36(3):211-224
pubmed: 31073762
J Exp Clin Cancer Res. 2016 Mar 25;35:55
pubmed: 27015814
Cancer Cell. 2021 Apr 12;39(4):509-528.e20
pubmed: 33577785
Int J Mol Sci. 2019 Jan 09;20(2):
pubmed: 30634433
Int J Mol Sci. 2021 Nov 22;22(22):
pubmed: 34830491
Acta Neuropathol Commun. 2018 Aug 21;6(1):81
pubmed: 30129426
Curr Drug Targets. 2009 Jul;10(7):581-9
pubmed: 19601762
Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1754-1769
pubmed: 29510196
Nat Cell Biol. 2018 Jul;20(7):823-835
pubmed: 29915361
Int J Mol Sci. 2020 May 30;21(11):
pubmed: 32486205
Cancer Cell. 2012 Mar 20;21(3):297-308
pubmed: 22439925
Clin Med Oncol. 2009 Apr 8;3:39-52
pubmed: 19777070
Sci Rep. 2017 Oct 23;7(1):13754
pubmed: 29062041
Breast Cancer Res. 2010;12(5):R68
pubmed: 20813035
Cell Death Dis. 2013 Aug 15;4:e767
pubmed: 23949216
Oncogene. 2004 Dec 16;23(58):9427-31
pubmed: 15543236
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Oncol Lett. 2016 Mar;11(3):1615-1620
pubmed: 26998052
Nat Rev Cancer. 2004 Apr;4(4):296-307
pubmed: 15057289
Front Immunol. 2020 Jul 17;11:1402
pubmed: 32765498
PLoS One. 2013;8(2):e56505
pubmed: 23457577
Int Immunopharmacol. 2012 Nov;14(3):283-8
pubmed: 22863814
J Cell Physiol. 2019 Nov;234(11):19750-19760
pubmed: 30937892
J Clin Oncol. 2019 Mar 20;37(9):741-750
pubmed: 30715997
Biomaterials. 2018 Apr;161:164-178
pubmed: 29421553
Neuro Oncol. 2017 Jul 1;19(7):887-896
pubmed: 28339582
Curr Opin Neurol. 2019 Dec;32(6):878-885
pubmed: 31592790
ASN Neuro. 2018 Jan-Dec;10:1759091418818261
pubmed: 30909720
Cancer Res. 2005 Sep 15;65(18):8250-5
pubmed: 16166301
Cell Stress. 2019 Jan 23;3(2):47-65
pubmed: 31225500
Aging (Albany NY). 2011 Mar;3(3):192-222
pubmed: 21422497
Brain Tumor Res Treat. 2014 Oct;2(2):124-7
pubmed: 25408938
N Engl J Med. 2013 Oct 17;369(16):1561-3
pubmed: 24131182
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
Brain Behav Immun. 2013 Aug;32:70-85
pubmed: 23454862
Nature. 2009 Oct 22;461(7267):1071-8
pubmed: 19847258
Contemp Oncol (Pozn). 2016;20(2):109-18
pubmed: 27358588
Oncotarget. 2011 Mar;2(3):135-64
pubmed: 21411864
Brain Tumor Res Treat. 2017 Apr;5(1):1-9
pubmed: 28516072
Nat Rev Cancer. 2020 Jan;20(1):57-70
pubmed: 31806884
Oncogene. 2017 Sep 21;36(38):5356-5368
pubmed: 28534507
Front Surg. 2016 Mar 02;3:11
pubmed: 26973839
Oncotarget. 2014 Dec 15;5(23):11752-77
pubmed: 25361007
Cancers (Basel). 2010 Apr 26;2(2):693-712
pubmed: 24281089
Biology (Basel). 2021 Aug 12;10(8):
pubmed: 34439999
Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12823-8
pubmed: 25136121
Br J Cancer. 2020 May;122(11):1580-1589
pubmed: 32291392
Semin Cancer Biol. 2020 Feb;60:262-273
pubmed: 31654711
Am J Cancer Res. 2017 May 01;7(5):1016-1036
pubmed: 28560055
J Oncol Pract. 2017 Oct;13(10):629-638
pubmed: 29020535
Cancer Lett. 2010 Dec 8;298(2):139-49
pubmed: 20947248
Int J Mol Sci. 2017 Nov 15;18(11):
pubmed: 29140300
Cancer Res. 2016 Aug 15;76(16):4708-19
pubmed: 27325644
Curr Neurol Neurosci Rep. 2013 May;13(5):345
pubmed: 23532369
Oncoimmunology. 2019 Oct 21;8(12):e1678921
pubmed: 31741780
Free Radic Res. 2015 May;49(5):511-24
pubmed: 25824967
J Biomed Res. 2013 Jul;27(4):254-71
pubmed: 23885265
Front Pharmacol. 2020 Apr 08;11:368
pubmed: 32322199
Int J Mol Med. 2016 Apr;37(4):998-1004
pubmed: 26936801
Pharmgenomics Pers Med. 2019 May 27;12:59-73
pubmed: 31213877
Lab Invest. 2006 Dec;86(12):1221-32
pubmed: 17075581
Oncotarget. 2019 Jan 29;10(9):920-921
pubmed: 30847018
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
Front Cell Dev Biol. 2021 Jul 01;9:683276
pubmed: 34277624
Chin J Cancer. 2011 Sep;30(9):590-602
pubmed: 21880180
Front Immunol. 2020 Oct 14;11:585616
pubmed: 33154756
Trends Immunol. 2007 Dec;28(12):519-24
pubmed: 17981504
Aging (Albany NY). 2012 May;4(5):330-49
pubmed: 22683550
J Neuropathol Exp Neurol. 1998 Feb;57(2):122-30
pubmed: 9600204
J Neuroinflammation. 2019 Oct 28;16(1):191
pubmed: 31660979
JCI Insight. 2017 Jan 26;2(2):e88815
pubmed: 28138554
Acta Pharmacol Sin. 2019 Oct;40(10):1292-1302
pubmed: 31015738
Acta Neuropathol. 2018 Nov;136(5):805-810
pubmed: 30259105
World J Clin Oncol. 2014 Aug 10;5(3):412-24
pubmed: 25114856
Cell Commun Signal. 2017 Oct 2;15(1):37
pubmed: 28969644
Int J Cancer. 2013 Feb 15;132(4):843-53
pubmed: 22752934
Front Oncol. 2020 Oct 19;10:571189
pubmed: 33194668
J Neurooncol. 2019 Jun;143(2):241-249
pubmed: 31025274
Cell Death Dis. 2016 Oct 27;7(10):e2434
pubmed: 27787518
Biomed Res Int. 2017;2017:7403747
pubmed: 29259986
Curr Neurol Neurosci Rep. 2016 Feb;16(2):13
pubmed: 26750128
Cancers (Basel). 2021 Nov 05;13(21):
pubmed: 34771718
J Biol Chem. 2013 Mar 29;288(13):9153-64
pubmed: 23408428
Adv Ther (Weinh). 2020 Jan;3(1):
pubmed: 31942443
Genes Dev. 2012 Apr 15;26(8):756-84
pubmed: 22508724
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Cells. 2017 Nov 22;6(4):
pubmed: 29165393
J Neurooncol. 2017 Jan;131(1):11-20
pubmed: 27633774
Nat Rev Cancer. 2005 Mar;5(3):231-7
pubmed: 15738985
Acta Neuropathol. 2016 Mar;131(3):365-78
pubmed: 26718201
Int J Mol Sci. 2019 Apr 23;20(8):
pubmed: 31018557
Int J Mol Sci. 2020 Jul 11;21(14):
pubmed: 32664581
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Lab Invest. 2000 Jun;80(6):837-49
pubmed: 10879735
Cancers (Basel). 2018 Sep 01;10(9):
pubmed: 30200436
Clin Transl Oncol. 2016 Nov;18(11):1062-1071
pubmed: 26960561
Cancer Treat Rev. 2019 Nov;80:101896
pubmed: 31541850
Cancers (Basel). 2020 Oct 04;12(10):
pubmed: 33020459
J Neuroimmunol. 2002 Nov;132(1-2):93-8
pubmed: 12417438
J Neuroinflammation. 2020 Nov 18;17(1):346
pubmed: 33208156
Medicine (Baltimore). 2019 Dec;98(50):e18194
pubmed: 31852075
Int J Mol Sci. 2021 Mar 24;22(7):
pubmed: 33804873
J Natl Compr Canc Netw. 2020 Nov 02;18(11):1537-1570
pubmed: 33152694
Nat Rev Cancer. 2008 Aug;8(8):618-31
pubmed: 18633355
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Rev Assoc Med Bras (1992). 2019 Mar;65(3):424-433
pubmed: 30994843
Clin Cancer Res. 2017 Nov 1;23(21):6650-6660
pubmed: 28751450
Br J Pharmacol. 2000 Jul;130(5):947-62
pubmed: 10882378
Cancers (Basel). 2021 Jun 03;13(11):
pubmed: 34204877
Cancers (Basel). 2019 Dec 31;12(1):
pubmed: 31906065
Neurol Sci. 2014 Jun;35(6):839-45
pubmed: 24362902
J Cell Mol Med. 2017 Oct;21(10):2563-2572
pubmed: 28488330
Nat Commun. 2019 Jun 11;10(1):2541
pubmed: 31186414
Neuro Oncol. 2017 Jan;19(1):43-54
pubmed: 27365097
PLoS One. 2015 Aug 28;10(8):e0137259
pubmed: 26317630
Int J Mol Sci. 2018 Nov 27;19(12):
pubmed: 30486451
Cancer Res. 2018 Sep 1;78(17):5060-5071
pubmed: 29976574
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Am J Pathol. 2012 Oct;181(4):1126-41
pubmed: 22858156
Front Oncol. 2021 Mar 09;11:644443
pubmed: 33768004
Genes Dev. 2015 Jun 15;29(12):1203-17
pubmed: 26109046

Auteurs

Filippo Torrisi (F)

Section of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Cristiana Alberghina (C)

Section of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Simona D'Aprile (S)

Section of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Anna M Pavone (AM)

Section of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Lucia Longhitano (L)

Section of Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Sebastiano Giallongo (S)

Section of Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Daniele Tibullo (D)

Section of Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Michelino Di Rosa (M)

Section of Anatomy, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Agata Zappalà (A)

Section of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Francesco P Cammarata (FP)

Institute of Molecular Bioimaging and Physiology, National Research Council-IBFM-CNR, 90015 Cefalù, Italy.
National Laboratory of South, National Institute for Nuclear Physics (LNS-INFN), 95125 Catania, Italy.

Giorgio Russo (G)

Institute of Molecular Bioimaging and Physiology, National Research Council-IBFM-CNR, 90015 Cefalù, Italy.
National Laboratory of South, National Institute for Nuclear Physics (LNS-INFN), 95125 Catania, Italy.

Massimo Ippolito (M)

Nuclear Medicine Department, AOE Cannizzaro, 95126 Catania, Italy.

Giacomo Cuttone (G)

National Laboratory of South, National Institute for Nuclear Physics (LNS-INFN), 95125 Catania, Italy.

Giovanni Li Volti (G)

Section of Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Nunzio Vicario (N)

Section of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Rosalba Parenti (R)

Section of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Classifications MeSH